Lu Z Y, Brochier J, Wijdenes J, Brailly H, Bataille R, Klein B
Laboratory for Immunological and Hematological Oncology, Nantes, France.
Eur J Immunol. 1992 Nov;22(11):2819-24. doi: 10.1002/eji.1830221110.
A patient with plasma cell leukemia was treated with anti-interleukin (IL)-6 monoclonal antibodies (mAb) for 2 months. Using chromatography on protein A-Sepharose, anti-murine-IgG-Sepharose, anti-IL-6-mAb-Sepharose and gel filtration at pH 2.3, we have demonstrated that the anti-IL-6 mAb, by preventing the binding of IL-6 to its cell membrane receptor and its renal elimination, has induced huge amounts of IL-6 to circulate in the form of monomeric immune complexes. By using this observation, we have developed a mathematical modelling that allows the determination of the overall daily production of IL-6 in this patient, which was in the range of 15 micrograms per day. Overall in vivo production of cytokines has never been evaluated in animals or in humans before.
一名浆细胞白血病患者接受抗白细胞介素（IL）-6单克隆抗体（mAb）治疗2个月。通过使用蛋白A-琼脂糖凝胶层析、抗鼠IgG-琼脂糖凝胶层析、抗IL-6-mAb-琼脂糖凝胶层析以及在pH 2.3条件下的凝胶过滤，我们证明，抗IL-6 mAb通过阻止IL-6与其细胞膜受体结合以及其经肾清除，已诱导大量IL-6以单体免疫复合物的形式循环。基于这一观察结果，我们建立了一个数学模型，该模型能够测定该患者体内IL-6的每日总生成量，其范围为每天15微克。此前从未在动物或人类中评估过细胞因子的整体体内生成情况。
